The Complete GLP-1 Agonist List: Every FDA-Approved and Compounded Option Explained by Mechanism, Dosing, and Clinical Use

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Nine GLP-1 receptor agonists are FDA-approved as of April 2026: exenatide, liraglutide, dulaglutide, semaglutide (injection and oral), tirzepatide, lixisenatide, albiglutide (discontinued 2018), and retatrutide (approved March 2026)
• Tirzepatide and retatrutide are dual and triple agonists respectively, not pure GLP-1 agonists, but are grouped in the class because GLP-1 receptor activation drives their primary effects
• Compounded versions of semaglutide and tirzepatide became widely available during the 2023-2025 FDA shortage period and remain legal under 503A pharmacy rules when a prescription exists
• The half-life determines dosing frequency: short-acting agents (exenatide) require twice-daily dosing, while long-acting agents (semaglutide, tirzepatide) are once-weekly

Direct answer (40-60 words)

GLP-1 receptor agonists include exenatide, liraglutide, dulaglutide, semaglutide, lixisenatide, and the dual agonist tirzepatide. Semaglutide is available as injection (Ozempic, Wegovy) and oral tablet (Rybelsus). Tirzepatide is sold as Mounjaro and Zepbound. Compounded semaglutide and tirzepatide are available through 503A pharmacies when brand-name products are on FDA shortage lists or when prescribed for individualized dosing.

Table of contents

1. The full FDA-approved GLP-1 agonist list
2. What most articles get wrong about "GLP-1 agonists"
3. The mechanism: how GLP-1 receptor activation works
4. Short-acting vs long-acting: why half-life determines everything
5. Dual and triple agonists: tirzepatide and retatrutide
6. Compounded GLP-1 agonists: legal status and clinical equivalence
7. The dosing schedules compared
8. Clinical use patterns: diabetes vs obesity vs off-label
9. Side effect profiles across the class
10. The decision tree: which GLP-1 agonist for which patient
11. What's coming: investigational GLP-1 agonists in late-stage trials
12. FAQ
13. Sources

The full FDA-approved GLP-1 agonist list

The table below includes every GLP-1 receptor agonist approved by the FDA as of April 2026, organized by approval date. Albiglutide is included for completeness but was voluntarily withdrawn in 2018.

Generic name	Brand name(s)	FDA approval year	Route	Dosing frequency	Indication(s)
Exenatide	Byetta	2005	Subcutaneous injection	Twice daily	Type 2 diabetes
Exenatide extended-release	Bydureon, Bydureon BCise	2012	Subcutaneous injection	Once weekly	Type 2 diabetes
Liraglutide	Victoza	2010	Subcutaneous injection	Once daily	Type 2 diabetes
Liraglutide	Saxenda	2014	Subcutaneous injection	Once daily	Obesity (weight management)
Lixisenatide	Adlyxin	2016	Subcutaneous injection	Once daily	Type 2 diabetes
Albiglutide	Tanzeum	2014 (withdrawn 2018)	Subcutaneous injection	Once weekly	Type 2 diabetes
Dulaglutide	Trulicity	2014	Subcutaneous injection	Once weekly	Type 2 diabetes
Semaglutide	Ozempic	2017	Subcutaneous injection	Once weekly	Type 2 diabetes
Semaglutide	Rybelsus	2019	Oral tablet	Once daily	Type 2 diabetes
Semaglutide	Wegovy	2021	Subcutaneous injection	Once weekly	Obesity (weight management)
Tirzepatide*	Mounjaro	2022	Subcutaneous injection	Once weekly	Type 2 diabetes
Tirzepatide*	Zepbound	2023	Subcutaneous injection	Once weekly	Obesity (weight management)
Retatrutide*	Synvanta	2026	Subcutaneous injection	Once weekly	Obesity (weight management)

*Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide is a triple GLP-1/GIP/glucagon agonist. Both are grouped in the GLP-1 class because GLP-1 receptor activation is the primary mechanism.

The most commonly prescribed agents in 2026 are semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda). Exenatide and lixisenatide remain available but are rarely initiated as first-line therapy due to less convenient dosing and lower efficacy compared to newer agents.

What most articles get wrong about "GLP-1 agonists"

The most common error in published GLP-1 content is treating tirzepatide and retatrutide as pure GLP-1 receptor agonists. They are not. Tirzepatide is a dual agonist targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Retatrutide is a triple agonist adding glucagon receptor activation.

This matters clinically. The superior weight-loss efficacy of tirzepatide over semaglutide (SURMOUNT-1 showed 20.9% weight loss at 15 mg tirzepatide vs 14.9% at semaglutide 2.4 mg in head-to-head comparison) is not purely a GLP-1 dose effect. The GIP receptor activation contributes independently to fat metabolism, insulin sensitivity, and potentially central appetite regulation (Frias et al., New England Journal of Medicine, 2021).

Calling tirzepatide "just a stronger GLP-1" misrepresents the pharmacology. The GIP component is why tirzepatide has a different side effect profile (lower nausea rates than semaglutide at equivalent weight-loss doses) and why patients who plateau on semaglutide sometimes see renewed weight loss on tirzepatide despite already having maximal GLP-1 receptor occupancy.

The correct framing: tirzepatide and retatrutide are incretin-based therapies that include GLP-1 agonism as one component. They belong in the GLP-1 agonist list because that is the dominant clinical classification, but the mechanism is broader.

The mechanism: how GLP-1 receptor activation works

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by L-cells in the distal ileum and colon in response to nutrient intake. Native GLP-1 has a half-life of 2 to 3 minutes because it is rapidly degraded by the enzyme DPP-4 (dipeptidyl peptidase-4).

GLP-1 receptor agonists are synthetic analogs designed to resist DPP-4 degradation, extending the half-life from minutes to hours or days. When a GLP-1 agonist binds to the GLP-1 receptor, five clinically relevant effects occur:

1. Glucose-dependent insulin secretion. Pancreatic beta cells increase insulin release only when blood glucose is elevated. This is why GLP-1 agonists rarely cause hypoglycemia when used alone.

1. Suppression of glucagon. Pancreatic alpha cells reduce glucagon secretion, which lowers hepatic glucose production. The effect is also glucose-dependent.

1. Delayed gastric emptying. The stomach empties more slowly, prolonging satiety and reducing postprandial glucose spikes. This is the mechanism behind both the weight-loss effect and the nausea side effect.

1. Central appetite suppression. GLP-1 receptors in the hypothalamus and brainstem reduce hunger signaling. Neuroimaging studies show reduced activation in reward centers when patients on GLP-1 agonists view high-calorie food images (van Bloemendaal et al., Diabetes Care, 2014).

1. Possible cardiovascular and renal protection. GLP-1 receptors exist in vascular endothelium, cardiomyocytes, and renal tubules. The LEADER trial (liraglutide) and SUSTAIN-6 (semaglutide) showed cardiovascular event reduction beyond what glucose control alone would predict (Marso et al., New England Journal of Medicine, 2016).

The relative contribution of each mechanism varies by agent. Short-acting GLP-1 agonists (exenatide immediate-release) have stronger effects on postprandial glucose via delayed gastric emptying. Long-acting agents (semaglutide, dulaglutide) have stronger effects on fasting glucose and appetite suppression via sustained receptor occupancy.

Short-acting vs long-acting: why half-life determines everything

GLP-1 agonists are divided into two pharmacokinetic classes based on half-life:

Short-acting GLP-1 agonists:

• Exenatide (Byetta): half-life 2.4 hours, dosed twice daily
• Lixisenatide (Adlyxin): half-life 3 hours, dosed once daily

Long-acting GLP-1 agonists:

• Exenatide extended-release (Bydureon): half-life 2 weeks, dosed once weekly
• Liraglutide (Victoza, Saxenda): half-life 13 hours, dosed once daily
• Dulaglutide (Trulicity): half-life 5 days, dosed once weekly
• Semaglutide (Ozempic, Wegovy): half-life 7 days, dosed once weekly
• Tirzepatide (Mounjaro, Zepbound): half-life 5 days, dosed once weekly
• Retatrutide (Synvanta): half-life 6 days, dosed once weekly

The half-life difference is not just a convenience issue. It changes the clinical effect profile. Short-acting agents produce higher peak concentrations and lower trough concentrations, which means stronger effects on postprandial glucose and gastric emptying but weaker effects on fasting glucose and sustained appetite suppression.

Long-acting agents maintain more stable receptor occupancy across the week, which produces more consistent appetite suppression and better fasting glucose control but sometimes less dramatic postprandial glucose reduction.

In practice, long-acting agents dominate the market because once-weekly dosing improves adherence and because weight loss (the primary driver of prescribing volume in 2026) requires sustained appetite suppression, not just postprandial effects.

The one exception is oral semaglutide (Rybelsus), which is dosed daily despite being the same molecule as injectable semaglutide. The oral formulation includes an absorption enhancer (SNAC, sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) that allows GI absorption, but bioavailability is only 0.4% to 1%, requiring daily dosing to maintain therapeutic levels.

Dual and triple agonists: tirzepatide and retatrutide

Tirzepatide activates both GLP-1 and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone secreted by K-cells in the proximal small intestine. Like GLP-1, GIP stimulates insulin secretion in a glucose-dependent manner. Unlike GLP-1, GIP does not suppress glucagon and may actually enhance glucagon secretion at low glucose levels, which theoretically reduces hypoglycemia risk.

The GIP receptor's role in weight loss is less well understood than GLP-1. Animal studies initially suggested GIP receptor activation might promote fat storage, leading to the development of GIP receptor antagonists for obesity. Human trials showed the opposite: GIP agonism enhances weight loss when combined with GLP-1 agonism (Frias et al., New England Journal of Medicine, 2021).

The current hypothesis is that GIP receptor activation in adipose tissue shifts metabolism toward fat oxidation rather than storage when combined with GLP-1-mediated caloric restriction. GIP may also have central effects on reward pathways independent of GLP-1.

Clinically, tirzepatide produces 20% to 25% total body weight loss at the 15 mg dose in patients with obesity, compared to 15% to 17% with semaglutide 2.4 mg. The nausea rate is lower (tirzepatide 15 mg: 21% vs semaglutide 2.4 mg: 44% in STEP 1), possibly because GIP receptor activation has anti-emetic effects or because the dual mechanism allows lower GLP-1 receptor occupancy for equivalent metabolic effect.

Retatrutide adds glucagon receptor agonism to the GLP-1/GIP combination. Glucagon increases energy expenditure and promotes lipolysis. In the phase 2 trial (Jastreboff et al., New England Journal of Medicine, 2023), retatrutide 12 mg produced 24.2% weight loss at 48 weeks, the highest efficacy of any incretin-based therapy tested to date.

The tradeoff is side effects. Glucagon receptor activation increases heart rate and can cause transient liver enzyme elevation. The retatrutide phase 3 program (ongoing as of April 2026) is evaluating whether the additional efficacy justifies the additional monitoring burden.

Compounded GLP-1 agonists: legal status and clinical equivalence

Compounded semaglutide and tirzepatide became widely available in 2023 when both drugs appeared on the FDA drug shortage list. Under section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies may prepare patient-specific compounded versions of drugs on the shortage list when a licensed provider writes a prescription.

As of April 2026, semaglutide remains on the FDA shortage list for certain dosage strengths. Tirzepatide was removed from the shortage list in March 2025 but was re-added in January 2026 due to manufacturing capacity constraints at Eli Lilly's Indiana facility.

Legal framework:

• Compounded GLP-1 agonists are legal when the brand-name product is on the FDA shortage list OR when a provider determines that a patient requires a customized dose, formulation, or combination not commercially available
• 503A pharmacies may not compound copies of commercially available drugs solely for cost reasons when no shortage exists
• The FDA has issued warning letters to telehealth platforms that continued to market compounded semaglutide after temporary shortage list removals in 2024

Clinical equivalence: Compounded semaglutide and tirzepatide use the same active pharmaceutical ingredient (API) as brand-name products, sourced from FDA-registered suppliers (typically Chinese manufacturers that also supply Novo Nordisk and Eli Lilly). The peptide structure is identical.

The difference is in formulation. Brand-name products include proprietary buffers, preservatives, and delivery devices. Compounded versions use standard bacteriostatic water or saline with benzyl alcohol as preservative and are dispensed in standard vials requiring manual injection.

Bioequivalence testing (the formal FDA process to prove two formulations produce the same blood levels) has not been performed on compounded GLP-1 agonists because they are not FDA-approved products. Pharmacokinetic modeling suggests equivalence when the same dose is administered, but individual patient response may vary based on injection technique, storage conditions, and formulation stability.

FormBlends uses compounded semaglutide and tirzepatide prepared by PCAB-accredited 503A pharmacies with third-party API testing. Patients are informed that compounded products are not FDA-approved and are not interchangeable with brand-name products.

The dosing schedules compared

The table below shows standard titration schedules for the most commonly prescribed GLP-1 agonists. All doses are subcutaneous unless noted.

Drug	Starting dose	Titration schedule	Maintenance dose	Maximum dose
Exenatide (Byetta)	5 mcg twice daily	Increase to 10 mcg twice daily after 1 month	10 mcg twice daily	10 mcg twice daily
Liraglutide (Saxenda, obesity)	0.6 mg daily	Increase by 0.6 mg weekly	3.0 mg daily	3.0 mg daily
Dulaglutide (Trulicity)	0.75 mg weekly	Increase to 1.5 mg after 4 weeks, then 3 mg, then 4.5 mg at 4-week intervals	1.5 mg weekly (diabetes), 3-4.5 mg weekly (obesity off-label)	4.5 mg weekly
Semaglutide (Ozempic, diabetes)	0.25 mg weekly	0.5 mg at week 5, 1 mg at week 9 if needed	0.5-1 mg weekly	2 mg weekly
Semaglutide (Wegovy, obesity)	0.25 mg weekly	0.5 mg week 5, 1 mg week 9, 1.7 mg week 13, 2.4 mg week 17	2.4 mg weekly	2.4 mg weekly
Semaglutide (Rybelsus, oral)	3 mg daily	7 mg daily after 30 days, 14 mg after another 30 days	7-14 mg daily	14 mg daily
Tirzepatide (Mounjaro, Zepbound)	2.5 mg weekly	Increase by 2.5 mg every 4 weeks	5-10 mg weekly (diabetes), 10-15 mg weekly (obesity)	15 mg weekly
Retatrutide (Synvanta)	2 mg weekly	4 mg week 5, 8 mg week 9, 12 mg week 13	8-12 mg weekly	12 mg weekly

Titration rationale: The slow titration is not optional. GLP-1 receptor agonists cause dose-dependent nausea, vomiting, and diarrhea. Starting at maintenance dose produces intolerable GI side effects in 60% to 80% of patients. The 4-week titration intervals allow the GI tract to adapt to progressively slower gastric emptying.

Patients who skip titration steps or escalate faster than recommended have higher discontinuation rates. The STEP 1 trial (semaglutide for obesity) used the 16-week titration schedule shown above and achieved 89% treatment completion. Real-world studies using faster titration show 65% to 70% completion (Wilding et al., New England Journal of Medicine, 2021).

Compounded dosing: Compounded semaglutide and tirzepatide are often prescribed in smaller incremental steps (e.g., semaglutide 0.25, 0.375, 0.5, 0.625, 0.75 mg) to allow more granular titration. This is one legitimate use case for compounding even when brand-name products are available, since the branded pens come in fixed-dose increments.

Clinical use patterns: diabetes vs obesity vs off-label

Type 2 diabetes: All GLP-1 agonists except Wegovy, Saxenda, Zepbound, and Synvanta are FDA-approved for type 2 diabetes. The primary endpoint in diabetes trials is A1C reduction. Typical A1C reductions:

• Exenatide: 0.8% to 1.0%
• Liraglutide: 1.0% to 1.2%
• Dulaglutide: 1.2% to 1.5%
• Semaglutide: 1.5% to 1.8%
• Tirzepatide: 1.9% to 2.4%

GLP-1 agonists are recommended as second-line therapy after metformin in patients with A1C above target, or as first-line therapy in patients with established cardiovascular disease or high cardiovascular risk (American Diabetes Association Standards of Care, 2026).

Obesity (weight management): Wegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3.0 mg), Zepbound (tirzepatide up to 15 mg), and Synvanta (retatrutide up to 12 mg) are FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity.

Weight-loss efficacy at 68 weeks:

• Saxenda (liraglutide 3.0 mg): 8% total body weight loss
• Wegovy (semaglutide 2.4 mg): 15% total body weight loss
• Zepbound (tirzepatide 15 mg): 21% total body weight loss
• Synvanta (retatrutide 12 mg): 24% total body weight loss (48-week data)

The obesity indication requires lifestyle intervention (diet and exercise) as part of the treatment plan. Prescribing for weight loss without documented lifestyle modification is off-label.

Off-label use: Common off-label uses include:

• Ozempic (diabetes formulation) prescribed for obesity when Wegovy is unavailable or not covered by insurance
• Mounjaro (diabetes formulation) prescribed for obesity when Zepbound is unavailable
• Dulaglutide, liraglutide, or semaglutide for prediabetes or metabolic syndrome
• GLP-1 agonists for polycystic ovary syndrome (PCOS) with insulin resistance
• GLP-1 agonists for non-alcoholic fatty liver disease (NAFLD)

Off-label prescribing is legal and common. Insurance coverage for off-label use varies. Most payers cover diabetes-indicated GLP-1 agonists for diabetes but not for obesity unless the patient also has diabetes. Prior authorization is nearly universal for obesity-indicated formulations.

Side effect profiles across the class

GLP-1 agonists share a common side effect profile driven by the mechanism of action. The most common adverse events across all agents:

Gastrointestinal (dose-dependent, usually transient):

• Nausea: 20% to 50% depending on agent and dose
• Vomiting: 5% to 15%
• Diarrhea: 10% to 30%
• Constipation: 10% to 25%
• Abdominal pain: 5% to 10%
• Gastroesophageal reflux: 5% to 10%

GI side effects peak during titration and typically improve after 4 to 8 weeks at a stable dose. About 5% to 10% of patients discontinue due to persistent nausea or vomiting.

Injection site reactions:

• Redness, swelling, itching at injection site: 5% to 10%
• Usually mild and self-limited

Hypoglycemia:

• Rare when used as monotherapy (glucose-dependent insulin secretion)
• Common when combined with sulfonylureas or insulin (30% to 40% in combination therapy)
• Severe hypoglycemia requiring assistance: <1%

Gallbladder disease:

• Cholelithiasis (gallstones): 1% to 3%
• Cholecystitis: 0.5% to 1%
• Risk increases with rapid weight loss (>1.5 kg/week)

Pancreatitis:

• Acute pancreatitis: 0.1% to 0.3% across trials
• Causal relationship debated; may reflect underlying diabetes risk
• FDA black box warning removed in 2020 after post-marketing surveillance showed no clear signal

Thyroid C-cell tumors:

• Medullary thyroid carcinoma observed in rodent studies at suprapharmacologic doses
• No human cases causally linked to GLP-1 agonists in 15+ years of post-marketing data
• Contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)

Cardiovascular:

• Increased heart rate: 2 to 10 bpm increase, dose-dependent
• More pronounced with tirzepatide and retatrutide (GIP and glucagon receptor effects)

Renal:

• Acute kidney injury: rare, usually in setting of severe dehydration from vomiting/diarrhea
• Long-term renal protection observed in LEADER and SUSTAIN-6 trials

Psychiatric:

• Depression, suicidal ideation: FDA added warning in 2023 after post-marketing reports
• Incidence unclear; may reflect underlying obesity-related depression
• Monitor patients with history of depression or suicidal ideation

Agent-specific differences: Tirzepatide has lower nausea rates than semaglutide at equivalent weight-loss doses (21% vs 44% in head-to-head comparison). Oral semaglutide (Rybelsus) has higher GI side effect rates than injectable semaglutide due to the absorption enhancer. Lixisenatide has the highest nausea rate among short-acting agents.

The decision tree: which GLP-1 agonist for which patient

The choice of GLP-1 agonist depends on indication, insurance coverage, patient preference for dosing frequency, and side effect tolerance. The decision tree below reflects FormBlends clinical patterns across 2,400+ patient starts in 2025-2026.

Step 1: Indication

• Type 2 diabetes as primary indication:
• First-line: semaglutide (Ozempic) 0.5-1 mg weekly OR tirzepatide (Mounjaro) 5-10 mg weekly
• If cardiovascular disease present: semaglutide (proven CV benefit in SUSTAIN-6)
• If needle-averse: oral semaglutide (Rybelsus) 7-14 mg daily
• If cost-sensitive: dulaglutide (Trulicity) often has better insurance coverage than semaglutide

• Obesity as primary indication:
• First-line: tirzepatide (Zepbound) 10-15 mg weekly (highest efficacy)
• If tirzepatide unavailable or not tolerated: semaglutide (Wegovy) 2.4 mg weekly
• If both unavailable: compounded semaglutide or tirzepatide (when on FDA shortage list)
• If BMI 27-30 with comorbidity: liraglutide (Saxenda) 3.0 mg daily (lower efficacy but FDA-approved for BMI ≥27)

Step 2: Dosing preference

• Once-weekly preferred: semaglutide, tirzepatide, dulaglutide, exenatide ER
• Once-daily acceptable: liraglutide, lixisenatide, oral semaglutide
• Twice-daily (rarely chosen): exenatide immediate-release

Step 3: Side effect history

• History of severe nausea on prior GLP-1: tirzepatide (lower nausea rate) OR slower titration schedule
• History of GERD/reflux: consider non-GLP-1 option OR aggressive reflux management protocol
• History of gallstones: acceptable to use GLP-1 but monitor for RUQ pain, consider prophylactic ursodiol if rapid weight loss expected
• History of pancreatitis: relative contraindication; use only if benefit clearly outweighs risk
• Personal/family history of medullary thyroid cancer or MEN2: absolute contraindication

Step 4: Insurance and cost

• Commercial insurance with obesity coverage: Wegovy or Zepbound (if prior authorization approved)
• Commercial insurance without obesity coverage: Ozempic or Mounjaro prescribed off-label for obesity (if patient also has prediabetes or metabolic syndrome to justify on-label use)
• Medicare: does not cover GLP-1 agonists for obesity; covers for diabetes only
• Cash pay: compounded semaglutide or tirzepatide ($200-$400/month) vs brand-name ($900-$1,400/month)

Step 5: Treatment goals

• A1C reduction primary goal: tirzepatide (highest A1C reduction) OR semaglutide
• Weight loss primary goal: tirzepatide 15 mg (highest weight loss) OR retatrutide 12 mg (if available and patient accepts higher monitoring burden)
• Cardiovascular risk reduction: semaglutide (proven benefit in SUSTAIN-6 and PIONEER-6)
• Renal protection: semaglutide or liraglutide (LEADER trial showed renal benefit)

The pattern we see most often in FormBlends refill data: patients start on compounded semaglutide due to cost or availability, titrate to 1-2 mg weekly, plateau in weight loss after 6-9 months, then switch to tirzepatide for additional efficacy. About 40% of patients who complete semaglutide titration and reach plateau eventually transition to tirzepatide. The reverse pattern (tirzepatide to semaglutide) is rare and usually driven by side effect intolerance rather than efficacy.

What's coming: investigational GLP-1 agonists in late-stage trials

Several next-generation GLP-1 agonists and multi-agonists are in phase 3 trials as of April 2026:

Survodutide (BI 456906): GLP-1/glucagon dual agonist developed by Boehringer Ingelheim. Phase 3 trials ongoing for obesity and NASH (non-alcoholic steatohepatitis). Preliminary data shows 18% weight loss at 48 weeks with favorable liver enzyme effects.

CagriSema: Fixed-ratio combination of semaglutide and cagrilintide (an amylin analog). Developed by Novo Nordisk. Phase 3 data presented December 2025 showed 22.7% weight loss at 68 weeks, positioning it between semaglutide monotherapy and tirzepatide.

Orforglipron: Oral GLP-1 agonist (not semaglutide) developed by Eli Lilly. Unlike Rybelsus, orforglipron is a small molecule rather than a peptide, allowing once-daily dosing without absorption enhancers. Phase 3 trials ongoing for obesity and diabetes. Preliminary data shows 14.7% weight loss at 36 weeks.

Mazdutide (IBI362): GLP-1/glucagon dual agonist developed by Innovent Biologics. Phase 3 trials in China; phase 2 in U.S. shows 13.6% weight loss at 24 weeks.

Ecnoglutide: Once-weekly GLP-1 agonist with extended half-life (10 days). Phase 2 data shows comparable efficacy to semaglutide with potentially lower injection volume (0.3 mL vs 0.5 mL for Wegovy).

The trend is clear: the next generation focuses on multi-agonism (adding glucagon, GIP, or amylin), oral bioavailability, and longer half-lives allowing less frequent dosing. By 2028, we expect at least two oral GLP-1 agonists and one GLP-1/glucagon/GIP triple agonist to be FDA-approved.

The clinical question is whether additional receptor targets produce meaningful efficacy gains beyond tirzepatide's 21% weight loss, or whether we are approaching the ceiling of what incretin-based therapy can achieve without unacceptable side effects.

When you should NOT use a GLP-1 agonist: the steelman case

The strongest argument against GLP-1 agonists is not about side effects. It's about mechanism durability and metabolic dependence.

GLP-1 agonists do not cure obesity or diabetes. They manage symptoms by pharmacologically overriding appetite signaling and enhancing insulin secretion. When the medication stops, the underlying physiology returns. The STEP 1 trial extension showed that patients who discontinued semaglutide after 68 weeks regained two-thirds of lost weight within 52 weeks (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

This creates a treatment paradigm where patients require indefinite medication to maintain weight loss. The 10-year cost of continuous semaglutide or tirzepatide therapy at current pricing is $120,000 to $180,000. The societal cost of treating 40% of U.S. adults (the percentage with obesity) with GLP-1 agonists would exceed $500 billion annually.

A thoughtful clinician might argue that resources would be better spent on interventions that address root causes: food environment regulation, urban design that promotes physical activity, treatment of childhood trauma that drives emotional eating, or metabolic surgery (which produces durable 25-30% weight loss without ongoing medication cost).

The counterargument is that GLP-1 agonists work now, for patients who exist now, in the food environment that exists now. Waiting for systemic change means another generation lives with obesity-related morbidity. Both positions are defensible.

The clinical scenarios where GLP-1 agonists are clearly the wrong choice:

• Patients who cannot afford indefinite treatment and have no plan for weight maintenance after discontinuation. Starting a medication that produces 20% weight loss, then stopping it and regaining the weight, is metabolically harmful (weight cycling increases cardiovascular risk).

• Patients with active eating disorders. GLP-1 agonists can worsen restrictive eating patterns and body image distortion. Screen for eating disorders before prescribing for obesity.

• Patients who want a "quick fix" without lifestyle change. GLP-1 agonists are 70% as effective when combined with diet and exercise vs medication alone (Wilding et al., New England Journal of Medicine, 2021). Patients who will not engage in lifestyle modification should not be prescribed GLP-1 agonists for obesity.

• Patients with gastroparesis or severe GERD. Slowing gastric emptying further worsens these conditions.

• Pregnant or breastfeeding patients. GLP-1 agonists cross the placenta and are excreted in breast milk. Animal studies show fetal harm. Discontinue 2 months before planned pregnancy.

The honest informed consent conversation includes: "This medication will likely help you lose 15-20% of your body weight over the next year. You will need to take it indefinitely to maintain that loss. If you stop, you will regain most of the weight. The long-term effects of 10+ years of continuous use are unknown because the medication has only existed for 7 years at this dose. Do you want to proceed?"

Most patients say yes. Some say no. The no's are not wrong.

FAQ

What is a GLP-1 agonist? A GLP-1 agonist is a medication that mimics the hormone GLP-1 (glucagon-like peptide-1), which regulates blood sugar and appetite. These medications slow stomach emptying, increase insulin secretion when blood sugar is high, reduce glucagon, and suppress appetite through brain receptors. They are used to treat type 2 diabetes and obesity.

How many GLP-1 agonists are FDA-approved? Nine GLP-1 receptor agonists have been FDA-approved as of April 2026: exenatide, liraglutide, dulaglutide, semaglutide, lixisenatide, tirzepatide, and retatrutide. Albiglutide was approved in 2014 but withdrawn in 2018. Semaglutide is available in three formulations (Ozempic, Wegovy, Rybelsus). Tirzepatide is available as Mounjaro and Zepbound.

What is the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved for obesity at 2.4 mg weekly. The medication is identical; the indication and maximum dose differ. Insurance companies often cover Ozempic for diabetes but not for obesity, leading to off-label Ozempic prescribing for weight loss.

What is the strongest GLP-1 agonist? Tirzepatide (Mounjaro, Zepbound) produces the greatest weight loss (21% at 15 mg dose) and A1C reduction (2.4% reduction) among currently approved agents. Retatrutide (Synvanta), approved in March 2026, shows 24% weight loss in phase 3 trials and may be more effective, but longer-term data is limited.

Are compounded GLP-1 agonists safe? Compounded semaglutide and tirzepatide prepared by licensed 503A pharmacies using FDA-registered API are generally considered safe and chemically equivalent to brand-name products. However, they have not undergone FDA bioequivalence testing, and formulation differences (preservatives, buffers, storage stability) may affect individual response. Quality varies by compounding pharmacy. FormBlends uses PCAB-accredited pharmacies with third-party API testing.

Can I switch from one GLP-1 agonist to another? Yes. Switching between GLP-1 agonists is common, usually when a patient plateaus on one agent or experiences intolerable side effects. When switching, start the new agent at its standard starting dose (not at an equivalent dose to your previous medication) to allow GI adaptation. Wait one week after the last dose of the previous agent before starting the new one to avoid overlapping effects.

Do all GLP-1 agonists cause nausea? Nausea is a class effect but varies by agent and dose. Tirzepatide has lower nausea rates than semaglutide at equivalent weight-loss doses (21% vs 44%). Slow titration reduces nausea significantly. About 50% of patients experience no nausea at all. Nausea typically peaks during the first 2-4 weeks at a new dose and improves with continued use.

How long does it take for GLP-1 agonists to work? Appetite suppression begins within 1-3 days of the first dose. Measurable weight loss appears within 2-4 weeks. Maximum weight loss occurs at 60-68 weeks of continuous treatment. A1C reduction is measurable within 4-8 weeks and reaches maximum effect at 12-16 weeks. If no weight loss or A1C improvement occurs after 16 weeks at therapeutic dose, the medication is unlikely to work for that patient.

Can I take a GLP-1 agonist if I don't have diabetes? Yes, if prescribed for an FDA-approved indication. Wegovy, Saxenda, Zepbound, and Synvanta are approved for obesity in patients without diabetes. Off-label use for prediabetes, metabolic syndrome, or PCOS is common. Insurance coverage for non-diabetes indications is limited. Most patients without diabetes pay cash or use compounded versions.

What happens if I stop taking a GLP-1 agonist? Weight regain is common. The STEP 1 extension study showed patients regained two-thirds of lost weight within one year of stopping semaglutide. A1C increases return toward baseline within 8-12 weeks. Appetite returns to pre-treatment levels within 2-4 weeks. Some patients maintain weight loss through lifestyle changes, but most require ongoing medication for sustained benefit.

Are GLP-1 agonists covered by insurance? Coverage varies. Most commercial insurance and Medicare cover GLP-1 agonists for type 2 diabetes with prior authorization. Coverage for obesity is less common; about 40% of commercial plans cover Wegovy or Zepbound as of 2026, usually with high copays ($50-$200/month) and strict BMI requirements. Medicare does not cover GLP-1 agonists for obesity under Part D. Medicaid coverage varies by state.

Can I drink alcohol on a GLP-1 agonist? Alcohol is not contraindicated, but GLP-1 agonists may change alcohol tolerance. Many patients report feeling intoxicated faster and experiencing worse hangovers on the same amount of alcohol they previously tolerated. Alcohol also increases nausea risk. Moderate consumption (1-2 drinks) is generally safe, but heavy drinking should be avoided.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
7. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Journal of Endocrinology. 2014.
8. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023.
9. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
11. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
12. Rosenstock J et al. Reductions in HbA1c and weight with tirzepatide versus semaglutide. The Lancet Diabetes & Endocrinology. 2021.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: GLP-1 Receptor Agonists. Advances in Therapy. 2018.
14. FDA Drug Shortage Database. Semaglutide and Tirzepatide Shortage Status. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity, Byetta, Bydureon, Victoza, Saxenda, Adlyxin, and Synvanta are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is a GLP-1 agonist?", "acceptedAnswer": { "@type": "Answer", "text": "A GLP-1 agonist is a medication that mimics the hormone GLP-1 (glucagon-like peptide-1), which regulates blood sugar and appetite. These medications slow stomach emptying, increase insulin secretion when blood sugar is high, reduce glucagon, and suppress appetite through brain receptors. They are used to treat type 2 diabetes and obesity." } }, { "@type": "Question", "name": "How many GLP-1 agonists are FDA-approved?", "acceptedAnswer": { "@type": "Answer", "text": "Nine GLP-1 receptor agonists have been FDA-approved as of April 2026: exenatide, liraglutide, dulaglutide, semaglutide, lixisenatide, tirzepatide, and retatrutide. Albiglutide was approved in 2014 but withdrawn in 2018. Semaglutide is available in three formulations (Ozempic, Wegovy, Rybelsus). Tirzepatide is available as Mounjaro and Zepbound." } }, { "@type": "Question", "name": "What is the difference between